Compare HOMB & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOMB | BLTE |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.0B |
| IPO Year | 2006 | 2021 |
| Metric | HOMB | BLTE |
|---|---|---|
| Price | $31.04 | $175.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $31.50 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.8M | 134.5K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | ★ 19.90 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.99 | N/A |
| Revenue Next Year | $5.14 | $492.11 |
| P/E Ratio | $26.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.50 | $60.00 |
| 52 Week High | $31.70 | $200.00 |
| Indicator | HOMB | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 70.08 |
| Support Level | $27.56 | $167.80 |
| Resistance Level | $31.70 | $183.67 |
| Average True Range (ATR) | 0.47 | 5.71 |
| MACD | -0.13 | 1.52 |
| Stochastic Oscillator | 61.45 | 91.62 |
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.